678 filings
Page 4 of 34
6-K
1s4974gl
8 Mar 23
Current report (foreign)
7:11pm
6-K
r3exw0iqoee0q9hjvwk
6 Mar 23
Current report (foreign)
7:09am
6-K
798yqj57
28 Feb 23
Current report (foreign)
7:02am
6-K
6kd0rlbohwy6t4ar2k2k
16 Feb 23
RedHill Announces Positive MHRA Meeting and Planned
8:01am
6-K
os2e vu2s
15 Feb 23
RedHill Biopharma Announces Positive FDA Meeting
7:02am
6-K
ofkmsoxzi esj5iw35k
6 Feb 23
RedHill Biopharma and HealthCare Royalty Agree to
7:02am
6-K
yk8zkdz
26 Jan 23
RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease
7:02am
6-K
jtpyk
25 Jan 23
Current report (foreign)
9:15am
6-K
tvcrzpxil7l5tlxcs
24 Jan 23
Current report (foreign)
9:00am
6-K
jz0yef i2
3 Jan 23
RedHill Announces Publication of Positive Phase 2 Study
7:02am
6-K/A
ri1uhy40oca1rf5ii
27 Dec 22
Current report (foreign) (amended)
7:00am
6-K
i2ybnstqbrf45u
20 Dec 22
Current report (foreign)
7:00am
6-K
9gvhw5b5
12 Dec 22
Current report (foreign)
7:00am
6-K
uyvaa3
6 Dec 22
Current report (foreign)
1:38pm
6-K
wj0 gd47hkpoii
5 Dec 22
Current report (foreign)
4:24pm
6-K
na7d8hxb0nfy0 s4
5 Dec 22
RedHill’s Aemcolo® Granted FDA QIDP 5-Year Exclusivity Extension
7:03am
6-K
kchgau4 xf9mnlw6
2 Dec 22
Current report (foreign)
9:00am
6-K
w9qnzigf5d9e0dpq
1 Dec 22
Current report (foreign)
4:01pm
6-K
ll8l7
29 Nov 22
RedHill Biopharma Announces Q3/22 Results and Non-binding agreement in principle reached with HCR on sale of Movantik to extinguish all debt
8:05am
6-K
90r5zqw1g37dpgx
17 Nov 22
RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation Injury
8:32am